Ester Prodrugs of Malonate with Enhanced Intracellular Delivery Protect Against Cardiac Ischemia-Reperfusion Injury In Vivo.
Authors
Prag, Hiran A
Pala, Laura
Kula-Alwar, Duvaraka
Mulvey, John F
Luping, Du
Beach, Timothy E
Booty, Lee M
Hall, Andrew R
Logan, Angela
Sauchanka, Volha
Caldwell, Stuart T
Robb, Ellen L
James, Andrew M
Xu, Zhelong
Saeb-Parsy, Kourosh
Hartley, Richard C
Murphy, Michael P
Publication Date
2022-02Journal Title
Cardiovasc Drugs Ther
ISSN
0920-3206
Publisher
Springer Science and Business Media LLC
Volume
36
Issue
1
Pages
1-13
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Prag, H. A., Pala, L., Kula-Alwar, D., Mulvey, J. F., Luping, D., Beach, T. E., Booty, L. M., et al. (2022). Ester Prodrugs of Malonate with Enhanced Intracellular Delivery Protect Against Cardiac Ischemia-Reperfusion Injury In Vivo.. Cardiovasc Drugs Ther, 36 (1), 1-13. https://doi.org/10.1007/s10557-020-07033-6
Abstract
PURPOSE: Mitochondrial reactive oxygen species (ROS) production upon reperfusion of ischemic tissue initiates the ischemia/reperfusion (I/R) injury associated with heart attack. During ischemia, succinate accumulates and its oxidation upon reperfusion by succinate dehydrogenase (SDH) drives ROS production. Inhibition of succinate accumulation and/or oxidation by dimethyl malonate (DMM), a cell permeable prodrug of the SDH inhibitor malonate, can decrease I/R injury. However, DMM is hydrolysed slowly, requiring administration to the heart prior to ischemia, precluding its administration to patients at the point of reperfusion, for example at the same time as unblocking a coronary artery following a heart attack. To accelerate malonate delivery, here we developed more rapidly hydrolysable malonate esters. METHODS: We synthesised a series of malonate esters and assessed their uptake and hydrolysis by isolated mitochondria, C2C12 cells and in mice in vivo. In addition, we assessed protection against cardiac I/R injury by the esters using an in vivo mouse model of acute myocardial infarction. RESULTS: We found that the diacetoxymethyl malonate diester (MAM) most rapidly delivered large amounts of malonate to cells in vivo. Furthermore, MAM could inhibit mitochondrial ROS production from succinate oxidation and was protective against I/R injury in vivo when added at reperfusion. CONCLUSIONS: The rapidly hydrolysed malonate prodrug MAM can protect against cardiac I/R injury in a clinically relevant mouse model.
Keywords
Original Article, Ischemia/reperfusion injury, Succinate, Malonate, Mitochondria, Drug delivery
Sponsorship
Medical Research Council (MR/P000320/1)
Medical Research Council (MC_U105663142)
Wellcome Trust (110159/Z/15/Z)
British Heart Foundation (PG/15/84/31670)
Identifiers
s10557-020-07033-6, 7033
External DOI: https://doi.org/10.1007/s10557-020-07033-6
This record's URL: https://www.repository.cam.ac.uk/handle/1810/333196
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk